Aimei Health Technology Co Ltd（AFJK）股票分析

AI 分析 of Aimei Health Technology Co Ltd (AFJK)

持有

Aimei Health Technology Co Ltd (AFJK) is currently not a strong buy. The stock is trading at $12.20, significantly down 83.92% year-to-date, indicating severe volatility and potential instability. The RSI is at 50.187, suggesting it is neither overbought nor oversold, but the forward P/E ratio is 0, indicating a lack of earnings expectations. The company has recently faced negative news, including a failure to file its quarterly report on time and the termination of a merger agreement, which has likely shaken investor confidence. The main risk is the company's recent net income drop to -83,144 USD in Q2 2026, which raises concerns about its financial health. Overall, while there may be potential for recovery, the current situation warrants a cautious approach and a hold position for now.

估值指標

Aimei Health Technology Co Ltd（AFJK）目前預期本益比為 0.00，5 年平均預期本益比為 0.00。

預期本益比

嚴重低估

5 年均值 P/E

0.00

目前P/E

0.00

高估

0.00

低估

0.00

預期 EV/EBITDA

嚴重低估

5 年均值 EV/EBITDA

0.00

目前EV/EBITDA

0.00

高估

0.00

低估

0.00

預期股價營收比

合理

5 年均值 P/S

0.11

目前P/S

0.00

高估

1.24

低估

-1.01

Alphio AI 對 AFJK 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%AFJK

$14.53

情境價格

基

基準

基準 · 50%AFJK

$12.44

情境價格

悲

悲觀

悲觀 · 25%AFJK

$10.38

情境價格

持有 AFJK 的大戶

W

W. R. Berkley Corporation

+ 持有AFJK

+4.37%

3個月報酬率

AFJK 常見問題 —— 由 Alphio AI 解答

Aimei Health Technology Co., Ltd. is a blank check company. The Company is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses or entities. The Company do not have any specific business combination under consideration and has not nor has anyone on behalf, directly or indirectly, contacted any prospective target business. It has not generated any revenues. It operates in the Financials sector.

Aimei Health Technology Co Ltd (AFJK) is currently not a strong buy. The stock is trading at $12.20, significantly down 83.92% year-to-date, indicating severe volatility and potential instability. The RSI is at 50.187, suggesting it is neither overbought nor oversold, but the forward P/E ratio is 0, indicating a lack of earnings expectations. The company has recently faced negative news, including a failure to file its quarterly report on time and the termination of a merger agreement, which has likely shaken investor confidence. The main risk is the company's recent net income drop to -83,144 USD in Q2 2026, which raises concerns about its financial health. Overall, while there may be potential for recovery, the current situation warrants a cautious approach and a hold position for now.